200
Participants
Start Date
December 11, 2019
Primary Completion Date
November 30, 2026
Study Completion Date
November 30, 2026
TSR-042 or Dostarlimab
Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.
capecitabine or 5-FU
Capecitabine 825mg/m2 BID concurrently with radiation per standard radiation guidelines. If patient is unable to tolerate oral medication, infusional 5-FU is an acceptable alternative.
Intensity Modulated Radiation Therapy (IMRT)
The radiation dose is 5400 cGy to the tumor and surrounding nodes 4700 cGy to the pelvis, with an integrated boost to the primary tumor and involved nodes of receiving 5400cGy in 27fx.
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Memorial Sloan Kettering Westchester - Limited Protocol Activities, Harrison
RECRUITING
Memorial Sloan Kettering Nassau - Limited Protocol Activities, Uniondale
RECRUITING
New York Cancer and Blood Specialists, Babylon
RECRUITING
Memorial Sloan Kettering Commack - Limited Protocol Activities, Commack
RECRUITING
Lehigh Valley Health Network (Data Collection Only), Allentown
RECRUITING
Baptist Alliance MCI (Data Collection Only), Miami
RECRUITING
Hartford Healthcare (Data Collection), Hartford
RECRUITING
Memorial Sloan Kettering Basking Ridge - Limited Protocol Activities, Basking Ridge
RECRUITING
Memorial Sloan Kettering Monmouth - Limited Protocol Activities, Middletown
RECRUITING
Memorial Sloan Kettering Bergen - Limited Protocol Activities, Montvale
Tesaro, Inc.
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER